PMID- 24757527
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140423
LR  - 20240323
IS  - 2080-4806 (Print)
IS  - 2080-4873 (Electronic)
IS  - 2080-4806 (Linking)
VI  - 66
IP  - 4
DP  - 2014
TI  - Renal cell carcinoma: how to hit the targets?
PG  - 394-404
LID - 10.5173/ceju.2013.04.art2 [doi]
AB  - INTRODUCTION: Renal cell carcinoma (RCC) is a widespread oncourological disease 
      with a tendency towards a slow increase of incidence. In the recent decade, there 
      has been development of numerous effective drugs targeted at different molecules 
      that play a dominant role in RCC carcinogenesis. Understanding of RCC 
      carcinogenesis confirms the key role of angiogenesis in maintaining the viability 
      of renal tumours and their metastases. MATERIAL AND METHODS: We aimed to 
      systemize numerous medicines, used to inhibit the angiogenesis in patients with 
      advanced RCC according to their targets, and to analyze their efficacy. RESULTS: 
      There are roughly four main mechanisms of action of the targeted drugs:Blockade 
      of circulating extracellular VEGF molecules.The selective blockade of tyrosine 
      kinase receptors' domains.The simultaneous blockage of the tyrosine kinase 
      receptors' domains and intracellular tyrosine kinases.The blockade of mammalian 
      target of rapamycin (mTOR) which is responsible for support of vital functions of 
      cancer cells. In addition to FDA officially approved drugs, numerous experimental 
      agents have been synthesized, which are currently on initial stages of clinical 
      studies in RCC treatment. CONCLUSIONS: The results of the currently used targeted 
      drugs demonstrate perspectives of metastatic RCC conservative treatment, that are 
      able to prolong cancer-specific survival in previously doomed patients for up to 
      29 months. The development of schedules for sequential treatment or combination 
      targeted therapy remains a current challenge. The quality of life is an important 
      factor that influences remedy choice. The advantages and disadvantages of 
      neoadjuvant and adjuvant targeted therapy are currently being intensively 
      discussed.
FAU - Banyra, Oleg
AU  - Banyra O
AD  - 2nd Lviv Municipal Polyclinic, Lviv, Ukraine.
FAU - Tarchynets, Marjan
AU  - Tarchynets M
AD  - Interpharmbiotek Scientific and Production Company, Kyiv, Ukraine.
FAU - Shulyak, Alexander
AU  - Shulyak A
AD  - State Institution "Institute of Urology at the National Academy of Medical 
      Sciences of Ukraine", Kyiv, Ukraine.
LA  - eng
PT  - Journal Article
DEP - 20140127
PL  - Poland
TA  - Cent European J Urol
JT  - Central European journal of urology
JID - 101587101
PMC - PMC3992446
OTO - NOTNLM
OT  - metastatic renal cell carcinoma
OT  - side-effects
OT  - survival
OT  - targeted therapy
EDAT- 2014/04/24 06:00
MHDA- 2014/04/24 06:01
PMCR- 2013/01/01
CRDT- 2014/04/24 06:00
PHST- 2013/07/02 00:00 [received]
PHST- 2013/10/07 00:00 [revised]
PHST- 2013/11/08 00:00 [accepted]
PHST- 2014/04/24 06:00 [entrez]
PHST- 2014/04/24 06:00 [pubmed]
PHST- 2014/04/24 06:01 [medline]
PHST- 2013/01/01 00:00 [pmc-release]
AID - 00305 [pii]
AID - 10.5173/ceju.2013.04.art2 [doi]
PST - ppublish
SO  - Cent European J Urol. 2014;66(4):394-404. doi: 10.5173/ceju.2013.04.art2. Epub 
      2014 Jan 27.